Andrey_Popov / Shutterstock.com
The English High Court has allowed Japan-based drug maker Fujifilm Kyowa Kirin Biologics to amend some of its arguments in a patent dispute surrounding AbbVie’s arthritis drug Humira (adalimumab).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Fujifilm Kyowa Kirin Biologics, biosimilar, English High Court, patent infringement, Mr Justice Henry Carr, Humira, adalimumab